BUSINESS
- HOME
- Business
- Drug Discovery Business
- Microparticle Technology
Microparticle Technology
Microparticle formulations are well-suited for the sustained release of compounds over extended periods. This is due to the biodegradability of the polymer forming the microparticles, which allows the drug encapsulated within them to be gradually released, maintaining a constant drug concentration throughout the body. While there is high demand for such formulations in pharmaceuticals, they are also characterized by the high difficulty of the formulation technology involved.
Our company is developing these sustained-release formulations. We have received technology transfer from Okada DDS Research Institute regarding formulation design for sustained-release injectables, establishing an integrated system covering feasibility studies, formulation design, and GMP manufacturing.
Our company is developing these sustained-release formulations. We have received technology transfer from Okada DDS Research Institute regarding formulation design for sustained-release injectables, establishing an integrated system covering feasibility studies, formulation design, and GMP manufacturing.
Feasibility Study Formulation Design for Long-Acting Sustained-Release Injections
Long-acting sustained-release formulations are highly sought-after products that reduce patient burden through fewer dosing schedules and improve quality of life.
We select the polymer most compatible with the drug from over 20 polymers with varying molecular weights, enabling final formulation design tailored to the desired sustained-release period.
[Candidate Polymers]
We maintain an inventory of approximately 20 types of polymers, including carboxylic acid-terminated and ester-terminated PLGA and PLA, sourced from domestic and international manufacturers (GMP compliant).
We select the polymer most compatible with the drug from over 20 polymers with varying molecular weights, enabling final formulation design tailored to the desired sustained-release period.
[Candidate Polymers]
We maintain an inventory of approximately 20 types of polymers, including carboxylic acid-terminated and ester-terminated PLGA and PLA, sourced from domestic and international manufacturers (GMP compliant).
Characteristics of Parkinson's Disease Treatment (Rotigotine) Sustained-Release Subcutaneous Injection
Expected Effects
・Reduced administration frequency compared to existing transdermal patches by utilizing a sustained-release injectable formulation
・Reduced burden on patients through fewer drug administration sessions
・Maintenance of blood concentration levels via long-term sustained release
・Reduced administration frequency compared to existing transdermal patches by utilizing a sustained-release injectable formulation
・Reduced burden on patients through fewer drug administration sessions
・Maintenance of blood concentration levels via long-term sustained release
Micro-Particle F/S Basic Set
1. Evaluation of polymer type effects
2. Evaluation of drug loading rate effects
3. Final formulation evaluation
4. Submission of final report
F/S Options (additional to basic set)
・Blood concentration measurement
1. Evaluation of polymer type effects
2. Evaluation of drug loading rate effects
3. Final formulation evaluation
4. Submission of final report
F/S Options (additional to basic set)
・Blood concentration measurement
SENTAN Pharma's proprietary formulation development — in vivo release evaluation — final formulation design
Scale-up and GMP manufacturing are conducted through a seamless system from research to GMP production via technical partnerships with domestic CMO companies
Advantages of SENTAN Pharma
